BMYBristol-Myers SquibbFinished
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Urinary Bladder Neoplasms · Muscle-Invasive Bladder Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 855 (final count)
- Started
- Nov 6, 2018
- Main results expected
- Feb 16, 2026
- Fully finished
- Apr 14, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathological Complete Response (pCR) rate, in all randomized participants
Measured over: Approximately 43 months
Event-Free Survival (EFS), in all randomized participants
Measured over: Approximately 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03661320 · record last updated 2026-09-10 · checked 2026-11-09 15:42 UTC